{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:04:13Z","timestamp":1793419453280,"version":"4.5.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"The most common adverse drug reaction from statins are statin-associated muscle symptoms (SAMS), characterized by myopathy (weakness), myalgia (muscle pain), and commonly elevation in serum creatine kinase. All statins are substrates of the organic anion transporter 1B1 (OATP1B1; gene: SLCO1B1<\/jats:italic>), albeit to different degrees. A genetic polymorphism in SLCO1B1<\/jats:italic>, c.521T>C (rs4149056), markedly decreases OATP1B1 function. The literature is currently unclear as to whether SLCO1B1<\/jats:italic> c.521T>C is significantly associated with discontinuation of atorvastatin specifically due to SAMS. Our hypothesis was that individuals carrying the SLCO1B1<\/jats:italic> decreased function 521C allele are more likely to discontinue atorvastatin due to SAMS. This was a retrospective analysis of survey data from 379 Caucasians genotyped for rs4149056 and treated with atorvastatin for at least 12\u2009months. Crude and multivariable logistic regression, adjusted for established risk factors for SAMS, determined the association of SLCO1B1<\/jats:italic> c.521T>C with discontinuation of atorvastatin due to SAMS (SLCO1B1<\/jats:italic> 521T-homozygotes vs. 521C-carriers). The sample was 51% male, with a mean age of 57\u2009years (SD\u2009=\u200911). Sixty-one percent of participants reported discontinuing atorvastatin due to SAMS, and 32% overall carried the 521C allele. SLCO1B1<\/jats:italic> 521C-carrier status was not a significant predictor of atorvastatin discontinuation in any model: crude OR\u2009=\u20091.07; 95% CI, 0.68\u20131.66; P<\/jats:italic>\u2009=\u20090.78 and adjusted OR\u2009=\u20091.07; 95% CI, 0.68\u20131.69; P<\/jats:italic>\u2009=\u20090.76. The results were similar in a sub-group of participants treated with higher doses of atorvastatin (>20\u2009mg). In summary, SLCO1B1<\/jats:italic> c.521T>C was not significantly associated with discontinuation of atorvastatin therapy due to SAMS.<\/jats:p>","DOI":"10.1097\/fpc.0000000000000412","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T04:24:05Z","timestamp":1590467045000},"page":"208-211","source":"Crossref","is-referenced-by-count":24,"title":["Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms"],"prefix":"10.1097","volume":"30","author":[{"given":"Derek W.","family":"Linskey","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"English","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Perry","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Ochs-Balcom","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Environmental Health, School of Public Health and Health Professions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health and Health Professions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Isackson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"},{"name":"Kaleida Health Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgirene D.","family":"Vladutiu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"},{"name":"Department of Neurology"},{"name":"Department of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine A.","family":"Luzum","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy.","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users.","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"35669","DOI":"10.1074\/jbc.M103792200","article-title":"Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.","volume":"276","author":"Tirona","year":"2001","journal-title":"J Biol Chem"},{"key":"R5-20230915","first-page":"128","article-title":"Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokinetic genetic variants.","volume":"5","author":"Talameh","year":"2014","journal-title":"J Pharmacogenomics Pharmacoproteomics"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1186\/s40064-016-2912-z","article-title":"Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis.","volume":"5","author":"Jiang","year":"2016","journal-title":"Springerplus"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"e1268","DOI":"10.1097\/MD.0000000000001268","article-title":"Association between SLCO1B1 Gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case-control studies.","volume":"94","author":"Hou","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","article-title":"SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.","volume":"94","author":"Carr","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.2174\/1381612825666181219163534","article-title":"Association of SLCO1B1 polymorphisms and atorvastatin safety and efficacy: a meta-analysis.","volume":"24","author":"Du","year":"2018","journal-title":"Curr Pharm Des"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/FPC.0000000000000018","article-title":"The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.","volume":"24","author":"de Keyser","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/mus.26397","article-title":"Clinical features related to statin-associated muscle symptoms.","volume":"59","author":"Ochs-Balcom","year":"2019","journal-title":"Muscle Nerve"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.cmet.2015.03.003","article-title":"GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals.","volume":"21","author":"Luzum","year":"2015","journal-title":"Cell Metab"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/mp200103h","article-title":"pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.","volume":"8","author":"Varma","year":"2011","journal-title":"Mol Pharm"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T01:01:21Z","timestamp":1694739681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000412","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,22]]}}}